Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose versus routine-dose low molecular weight heparin after total joint arthroplasty
ChiCTR2100042473Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium in hip osteoarthritis, disorders of knee, osteoarthritis (OA) and 3 more (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Antifactor Xa activity, Ecchymosis and 4 more. Started Jan 2021; status: recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
hip osteoarthritisdisorders of kneeosteoarthritis (OA)rheumatoid arthritis (RA)Post-traumatic osteoarthritis (PTOA)
Beyond the preview
Go deeper on ChiCTR2100042473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042473.